2638 Effectiveness of 2nd-line and subsequent therapies after pazopanib (Paz) in patients (pt) with metastatic renal cell carcinoma (mRCC): Final results of the SPAZO study (SOGUG). (September 2015) - Arija, J.A. Arranz; Pérez-Valderrama, B.; González-Larriba, J.L.; Rodríguez Sánchez, A.; Chirivella, I.; Pinto, A.; Marrero, R.D. García; Rubio, G.; García, J.M. Jurado; Borrega, P.; Quintela, M. Lázaro; Castellano, D.E.; et al.